| 杜丽娟,白文梅,王 兵,同立宏,刘莹莹.重组人血管内皮抑制素联合胸腺肽对肺癌合并恶性胸腔积液患者血清炎症因子和免疫功能的影响[J].,2019,19(9):1711-1714 |
| 重组人血管内皮抑制素联合胸腺肽对肺癌合并恶性胸腔积液患者血清炎症因子和免疫功能的影响 |
| Effect of Recombinant Human Endostatin Combined with Thymosin on the Serum Inflammatory Factors and Immune Function of Lung Cancer Patients with Malignant Pleural Effusion |
| 投稿时间：2018-08-30 修订日期：2018-09-23 |
| DOI：10.13241/j.cnki.pmb.2019.09.023 |
| 中文关键词: 重组人血管内皮抑制素 胸腺肽 肺癌 恶性胸腔积液 免疫功能 炎症因子 |
| 英文关键词: Recombinant human endostatin Thymosin Lung cancer Malignant pleural effusion Immune function Inflammatory factors |
| 基金项目:新疆维吾尔自治区自然科学基金项目(2015211c149) |
|
| 摘要点击次数: 780 |
| 全文下载次数: 648 |
| 中文摘要: |
| 摘要 目的：研究重组人血管内皮抑制素联合胸腺肽对肺癌合并恶性胸腔积液患者血清炎症因子和免疫功能的影响。方法：选择2015年1月～2017年12月我院收治的60例肺癌合并恶性胸腔积液患者，并将其随机分成两组。对照组将60 mg重组人血管内皮抑制素经引流管缓慢注入患者的胸腔内，观察组联合将300 mg胸腺肽经引流管缓慢注入患者的胸腔内。治疗8周后，对比两组的治疗有效率，治疗前后的血清白介素-6、肿瘤坏死因子-α以及白介素-23水平、每分钟最大通气量(Maximum ventilation per minute，MVV)、1秒钟用力呼气量占用力肺活量比值（forced expiratory volume in one second to forced vital capacity ratio，FEV1/FVC)、CD8+、CD4+及CD4+/CD8+的改变情况。结果：治疗后，观察组的有效率为86.67%，明显高于对照组(P<0.05)。两组治疗后的MVV和FEV1/FVC均较治疗前明显升高(P<0.05)，且观察组MVV和FEV1/FVC均明显高于对照组(P<0.05)。两组治疗后的血清白介素-6、肿瘤坏死因子-α以及白介素-23水平均较治疗前明显降低(P<0.05)，且观察组以上指标均显著低于对照组(P<0.05)。观察组治疗后的CD4+/CD8+以及CD4+均明显高于对照组(P<0.05)，CD8+明显低于对照组(P<0.05)。结论：重组人血管内皮抑制素联合胸腺肽可以改善减轻肺癌合并恶性胸腔积液患者的免疫功能，减轻机体的炎症状态，改善肺功能，提高治疗效果。 |
| 英文摘要: |
| ABSTRACT Objective: To study the effect of recombinant human vascular endostatin combined with thymosin on the serum in- flammatory factors and immune function of lung cancer patients with malignant pleural effusion. Methods: 60 cases of lung cancerpa- tients complicated with malignant pleural effusion who were treated in our hospital from January 2015 to December 2017 were selected and randomly divided into two groups. The control group was given 60 mg recombinant endostatin into the thoracic cavity through the drainage tube, and the observation group was given 300 mg thymosin through the drainage tube. After 8 weeks of treatment, the effec- tiveness, the changes of serum levels of interleukin-6, TNF-α, interleukin-23, MVV, FEV1/FVC, CD8+, CD4+, CD4+/CD8+ before and af- ter treatment were compared between two groups. Results: After treatment, the effective rate of observation group was 86.67%, which was significantly higher than that of the control group (P<0.05). The MVV and FEV1/FVC of both groups after treatment were signifi- cantly higher than those before treatment (P<0.05), and the MVV and FEV1/FVC of observation group were significantly higher than those in the control group (P<0.05). The levels of serum interleukin -6, tumor necrosis factor –α and interleukin -23 after treatment in both groups were significantly lower than those before treatment (P<0.05), and the above indexes were significantly lower in the observation group than those in the control group(P<0.05). The CD4+/CD8+ and CD4+ of observation group after treatment were significantly higher than those of the control group (P<0.05), and CD8+ was significantly lower than that of the control group (P<0.05). Conclusion: Recombi- nant human vascular endostatin combined with thymosin can improve the immune function of lung cancerpatients with malignant pleural effusion, it can relevel the inflammatory response, improve the lung function and the therapeutic effect. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
